Free Trial

Zevra Therapeutics (ZVRA) Stock Price, News & Analysis

Zevra Therapeutics logo
$9.26 -0.10 (-1.01%)
As of 03:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Zevra Therapeutics Stock (NASDAQ:ZVRA)

Key Stats

Today's Range
$9.26
$9.47
50-Day Range
$8.81
$12.79
52-Week Range
$6.19
$13.16
Volume
572,911 shs
Average Volume
754,693 shs
Market Capitalization
$520.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.71
Consensus Rating
Buy

Company Overview

Zevra Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

ZVRA MarketRank™: 

Zevra Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 328th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Zevra Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Zevra Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Zevra Therapeutics are expected to grow in the coming year, from ($1.95) to $0.20 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zevra Therapeutics is -44.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zevra Therapeutics is -44.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Zevra Therapeutics has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Zevra Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.59% of the float of Zevra Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Zevra Therapeutics has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Zevra Therapeutics has recently decreased by 5.31%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Zevra Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Zevra Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.59% of the float of Zevra Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Zevra Therapeutics has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Zevra Therapeutics has recently decreased by 5.31%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Zevra Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Zevra Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 16 people have searched for ZVRA on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zevra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $45,800.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 2.40% of the stock of Zevra Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 35.03% of the stock of Zevra Therapeutics is held by institutions.

  • Read more about Zevra Therapeutics' insider trading history.
Receive ZVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZVRA Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
See More Headlines

ZVRA Stock Analysis - Frequently Asked Questions

Zevra Therapeutics' stock was trading at $8.34 at the beginning of 2025. Since then, ZVRA stock has increased by 13.5% and is now trading at $9.4650.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.15. The firm had revenue of $20.40 million for the quarter, compared to analysts' expectations of $16.96 million. Zevra Therapeutics had a net margin of 4.33% and a negative trailing twelve-month return on equity of 112.40%.
Read the conference call transcript
.

Zevra Therapeutics' top institutional shareholders include Adage Capital Partners GP L.L.C. (7.43%), Rubric Capital Management LP (3.49%), Geode Capital Management LLC (2.27%) and 683 Capital Management LLC (2.00%). Insiders that own company stock include Neil F Mcfarlane, R Laduane Clifton, John B Bode, Joshua Schafer, Thomas Anderson, Matthew R Plooster, Timothy J Sangiovanni, Corey Michael Watton and Tamara A Seymour.
View institutional ownership trends
.

Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Tesla (TSLA).

Company Calendar

Last Earnings
5/13/2025
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ZVRA
CIK
1434647
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$29.00
Low Price Target
$18.00
Potential Upside/Downside
+150.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$105.51 million
Net Margins
4.33%
Pretax Margin
34.52%
Return on Equity
-112.40%
Return on Assets
-37.67%

Debt

Debt-to-Equity Ratio
0.52
Current Ratio
7.85
Quick Ratio
7.81

Sales & Book Value

Annual Sales
$23.61 million
Price / Sales
22.50
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.09 per share
Price / Book
4.53

Miscellaneous

Outstanding Shares
56,130,000
Free Float
54,788,000
Market Cap
$531.27 million
Optionable
Optionable
Beta
1.87
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ZVRA) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners